Peptide News Digest

North Sea Weight Limit Takes Effect, Anaphylaxis to Oral Semaglutide, Thymosin in Colorectal Cancer

A 124kg limit for North Sea workers starts as some use weight-loss jabs, a semaglutide anaphylaxis case, and a thymosin review in colorectal cancer.

9 stories · Covering industry, research, clinical-trials

Editor's Note

From November 1, anyone heavier than 124kg can no longer fly to a North Sea oil or gas platform, and STV reported that some workers turned to weight-loss injections to stay under the line, with one doctor saying some platforms needed bigger fridges for the pens. It is an unusual case of an employer safety rule, rather than a doctor or insurer, setting a weight target that drugs help people reach. The research this Sunday is mostly about the edges of GLP-1 use: a woman who went into anaphylaxis on oral semaglutide and kept taking it after a 13-step desensitization, a small study looking for a blood marker of who does better after switching to tirzepatide, and a network meta-analysis of insulin and GLP-1 combination shots. Beyond GLP-1 drugs, a review of 30 studies found thymosin preparations raised some immune counts in colorectal cancer patients but called the evidence too weak for routine use, and the antimicrobial peptide database DBAASP passed 25,000 entries.

Industry

North Sea's 124kg Helicopter Weight Limit Takes Effect, and Some Offshore Workers Used Weight-Loss Jabs to Get Under It

From November 1, 2026, offshore workers must weigh under 124kg (19.5 stone), the most a rescue helicopter winch can lift in an evacuation, under a rule set by trade body Offshore Energies UK, STV News reported. About 2,200 workers were over the limit in early 2025 and 840 earlier in 2026, and an estimated 241 to 300 may still be over it and could lose their jobs. Some workers turned to weight-loss injections, and Dr Stuart Scott, who works in offshore health care, said some platforms had to get bigger fridges to hold them.

#offshore-workers #occupational-health #uk #glp-1
Research

Woman Who Had Anaphylaxis on Oral Semaglutide Resumed It After a 13-Step Desensitization Protocol

A 60-year-old woman developed hives, facial swelling, a closing throat, and trouble breathing within minutes of taking oral semaglutide 3 mg and needed an epinephrine injection, clinicians reported in Allergologia et Immunopathologia. An intradermal skin test was positive, pointing to an IgE allergy. Because the drug was helping her and she had no good alternative, they gave a rapid 13-step oral desensitization with premedication, and she has stayed symptom-free on daily therapy since September 2025; the authors say no standard protocol exists.

#semaglutide #oral-semaglutide #anaphylaxis #desensitization
Research

In 90 Patients Switched From a GLP-1 Drug to Tirzepatide, a Blood-Cell GIP Receptor Reading Tracked With More Weight Loss

In a single-center retrospective study of 90 people with type 2 diabetes who had taken a GLP-1 drug for at least six months before switching to tirzepatide, higher baseline GIP receptor gene expression in blood monocytes was associated with larger drops in body weight and in the FIB-4 liver fibrosis score over six months, Hideyuki Okuma reported in Diabetology International. The author calls it an exploratory marker and says the study did not establish causation or actual reversal of liver scarring.

#tirzepatide #gip #switching #type-2-diabetes
Clinical Trials

Network Meta-Analysis of 30 Trials Finds Every Insulin-Plus-GLP-1 Combination Shot Beat Basal Insulin Alone on A1C and Weight

Endocrinologists from Bangladesh, India, and the UK pooled 30 randomized trials with 17,862 adults with type 2 diabetes and reported in Endocrine that all fixed-ratio combinations of basal insulin and a GLP-1 drug lowered A1C and body weight more than basal insulin alone. Compared with basal insulin, HR17031 had the largest estimated extra A1C drop (0.72 points) and IcoSema, Novo Nordisk's insulin icodec plus semaglutide, the largest extra weight loss (3.16 kg), but no HR17031 comparison with another combination was statistically significant, and certainty was mostly low to moderate.

#icosema #fixed-ratio-combination #basal-insulin #type-2-diabetes #semaglutide
Research

Review of 30 Studies Finds Thymosin Raised Some Immune Counts in Colorectal Cancer Patients but Evidence Is Too Weak for Routine Use

Researchers at the First Affiliated Hospital of Henan University of Chinese Medicine reviewed 30 studies with 2,514 colorectal cancer patients, including 25 randomized trials, in which thymosin preparations were added to the same anticancer treatment, publishing in Frontiers in Oncology. After surgery, thymosin was linked to higher CD4 percentages, CD4/CD8 ratios, and natural killer cell percentages, and some trials reported better performance scores, but effects on neutropenia were inconclusive and only one trial gave comparable survival data. Certainty was low or very low, and the authors say current evidence does not support routine use.

#thymosin #cancer #immunotherapy
Research

Antimicrobial Peptide Database DBAASP Reaches Version 4 With More Than 25,000 Entries and Chemical Structures for Machine Learning

The Database of Antimicrobial Activity and Structure of Peptides, curated at the Ivane Beritashvili Center of Experimental Biomedicine in Tbilisi with NIAID collaborators, released version 4, described in Nucleic Acids Research. It now holds more than 25,000 entries linking peptides to measured antimicrobial, antibiofilm, anticancer, and toxicity results under stated test conditions, and adds SMILES chemical structures, synergy records, and more than 9,200 molecular-dynamics simulations to help train prediction models.

#antimicrobial-peptides #database #machine-learning
Research

Beijing Team's Copper-Peptide Nanospheres Turn Ultrasound Into Tumor-Killing Oxygen Radicals and Carry a Protein Degrader in Mice

Beijing University of Chemical Technology researchers coordinated copper ions with the dipeptide diphenylalanine to build nanospheres that generate reactive oxygen species under ultrasound, then loaded them with a PROTAC that degrades the cancer-linked proteins BRD3 and BRD4, reporting in Small. The combination with ultrasound killed 91.3% of HeLa cervical cancer cells in culture and inhibited tumor growth by 92.6% in tumor-bearing mice; there is no human data.

#sonodynamic-therapy #protac #self-assembling-peptides #cancer
Research

China Pharmaceutical University Locks Short Peptides Into Helices With a 4-Mercaptoproline Cap to Block the Cancer Protein MDM2

China Pharmaceutical University chemists reported in Organic Letters that capping a peptide's starting end with 4-mercaptoproline and cross-linking it to an internal cysteine holds short peptides in the helical shape needed to block protein-protein interactions inside cells. Tuning the cap's stereochemistry and the cross-linker improved helicity, cell uptake, resistance to breakdown, and binding to MDM2, and the peptides reduced cancer cell viability, growth, and migration in lab tests.

#stapled-peptides #mdm2 #cancer
Research

Fudan University's 31-Residue FluoP-Tag Lights Up Proteins in Living Cells Without a Wash Step, Brighter Than HaloTag in Arrays

Fudan University researchers paired a 31-amino-acid peptide tag with a dye, FluoP580, that only becomes fluorescent when it binds the peptide, so proteins in living cells can be labeled without washing away excess dye, they reported in Angewandte Chemie. An array of eight tags was 3.37 times brighter than HaloTag labeled with a rhodamine probe while being smaller, about 29.5 kDa versus 33 kDa, and it imaged proteins in stress granules, the nucleus, and the cytoskeleton.

#peptide-tags #imaging #fluorescence

Related Guides